SLC16A3

SLC16A3 (MCT4) is an H⁺-coupled, pH-dependent monocarboxylate transporter that exports lactate across the plasma membrane and thereby couples glycolytic metabolism to extracellular signaling in cancer (PMID:27236641, PMID:36104287). It mediates l-lactate uptake/efflux with kinetics characterized in epithelial and hepatocellular carcinoma cells, and in polarized epithelium it functions specifically as a basolateral efflux transporter (PMID:26854723, PMID:36104287); its lactate-transport activity is non-competitively inhibited by diclofenac and by paralog-selective small molecules developed against it (PMID:27236641, PMID:37516113). Transcriptionally, SLC16A3 is a hypoxia-responsive gene directly activated by HIF-1α binding a promoter HRE, repressed by FBI-1/ZBTB7A, and de-repressed when NF-κB (RelA/p65) downregulates ZBTB7A; promoter CpG methylation independently silences its expression (PMID:23881922, PMID:31271899). Beyond transcription, surface delivery and activity of the transporter are controlled post-transcriptionally: CK2 phosphorylates SLC16A3 at Ser436 downstream of mutant KRAS–PI3K–AKT–mTORC1–HIF1α to enable its oncogenic function (PMID:39854318), and EGF-driven secretory autophagy traffics SLC16A3 together with its CD147/BSG chaperone to the plasma membrane via an LC3–SLC16A3 interaction (PMID:41948828). Functionally, SLC16A3-mediated lactate export drives tumor progression and immune evasion by activating GPR81–ERK–c-MYC autocrine loops, promoting M2 macrophage polarization, suppressing CD8⁺ T cells and limiting anti-PD-1 efficacy, and conferring resistance to ferroptosis and to gefitinib (PMID:38522774, PMID:41293164, PMID:42028950, PMID:41432987). Loss of SLC16A3 reverses these phenotypes, inducing ferroptosis through loss of GPX4/DHODH/SLC7A11 and triggering p38-MAPK/caspase-3-dependent apoptosis (PMID:39303526, PMID:41475270).

1. 2008 Medium

   Established that SLC16A3/MCT4 is expressed and membrane-localized in a glucose-dependent manner during early development, the first link between its expression and metabolic substrate availability.

   Evidence Immunofluorescence and RT-PCR under varying glucose conditions in preimplantation mouse embryos

   PMID:18385447

   Open questions at the time

   • Does not establish transport kinetics or H⁺-coupling
   • Nuclear distribution observed but unexplained mechanistically
2. 2013 Medium

   Identified promoter CpG methylation as a transcriptional control point silencing MCT4 expression in renal cancer.

   Evidence Promoter reporter assays in RCC cell lines with methylation–expression correlation in patient cohorts

   PMID:23881922

   Open questions at the time

   • Methylating/demethylating enzymes not identified
   • Does not connect methylation status to transporter activity or downstream phenotype
3. 2016 High

   Directly demonstrated MCT4's transport function—l-lactate cotransport—and provided a pharmacological inhibitor (diclofenac) and a polarity assignment (basolateral efflux).

   Evidence Radiolabeled l-lactate uptake with kinetic inhibition in Caco-2, Xenopus oocyte expression, and transepithelial transport/immunofluorescence localization

   PMID:26854723 PMID:27236641

   Open questions at the time

   • Stoichiometry of H⁺ coupling not quantified
   • Substrate range beyond lactate/ferulic acid not mapped
4. 2019 High

   Resolved the hypoxia-responsive transcriptional circuit controlling SLC16A3: direct HIF-1α activation, ZBTB7A/FBI-1 repression, and NF-κB-mediated de-repression.

   Evidence Promoter reporter assays, ChIP, oligonucleotide pulldown, and knockdown/overexpression of FBI-1 and RelA/p65 in colon cancer cells

   PMID:31271899

   Open questions at the time

   • Quantitative interplay between methylation and HIF/NF-κB inputs unresolved
   • Tissue-specificity of this circuit untested
5. 2022 Medium

   Confirmed MCT4 as a functionally dominant lactate transporter in hepatocellular carcinoma, distinguishing it from MCT2.

   Evidence pH-dependent l-lactate uptake with selective inhibitors and siRNA knockdown of MCT1/2/4 in HepG2 and Huh-7

   PMID:36104287

   Open questions at the time

   • Relative contributions of MCT1 vs MCT4 not fully separated
   • Single tumor type
6. 2023 Medium

   Provided a paralog-selective chemical probe (slCeMM1) exploiting SLC16A1/SLC16A3 synthetic lethality, enabling specific pharmacological dissection of MCT4.

   Evidence Isogenic cell survival assay cascade, ~90,000-compound screen, and chemoproteomic selectivity validation

   PMID:37516113

   Open questions at the time

   • Binding site on SLC16A3 not structurally defined
   • In vivo efficacy of probe not established here
7. 2024 Medium

   Connected SLC16A3 lactate export to immune evasion, showing it suppresses CD8⁺ T cells and limits anti-PD-1 response.

   Evidence Overexpression and genetic/pharmacological inhibition in B16-F10 with lactate measurement, CD8⁺ T cell assays, and in vivo anti-PD-1 models

   PMID:38522774

   Open questions at the time

   • Receptor mediating T cell suppression not defined in this study
   • Lactate vs acidification contribution not separated
8. 2024 Medium

   Linked SLC16A3 lactate efflux to ferroptosis resistance via ERK signaling and the GPX4/DHODH/SLC7A11 axis.

   Evidence siRNA knockdown with ERK/GPX4/DHODH/SLC7A11 Western blots and ROS/lipid peroxidation assays in HCC cells

   PMID:39303526

   Open questions at the time

   • Direct causal chain from lactate to GPX4 not dissected
   • No in vivo confirmation in this report
9. 2025 High

   Identified post-translational regulation: CK2-mediated Ser436 phosphorylation downstream of mutant KRAS–PI3K–AKT–mTORC1–HIF1α is required for SLC16A3 oncogenicity.

   Evidence Pathway inhibitor experiments, phosphosite mapping, S436 mutagenesis, CK2 kinase assay, xenografts and patient-derived organoids in iCCA

   PMID:39854318

   Open questions at the time

   • How S436 phosphorylation alters transport or trafficking mechanistically unresolved
   • Other phosphosites not excluded
10. 2025 Medium

    Extended ferroptosis resistance to a HIF1A-SLC16A3 axis conferring gefitinib resistance, with lactate rescue establishing transporter function as the effector.

    Evidence TF prediction, luciferase reporter, ferroptosis indicators, lactate rescue, and xenografts in lung adenocarcinoma

    PMID:41293164

    Open questions at the time

    • Mechanism by which lactate suppresses lipid peroxidation not defined
    • Single resistance context (gefitinib)
11. 2025 Medium

    Defined a SLC16A3–p38-MAPK–caspase-3 axis explaining apoptosis upon transporter loss in lung cancer.

    Evidence siRNA knockdown, phospho-kinase array, p38 inhibition (SB203580), and caspase-3 activity/clonogenic assays

    PMID:41475270

    Open questions at the time

    • Whether p38 activation is metabolic or transport-independent unclear
    • Link to ferroptosis pathway not integrated
12. 2025 Medium

    Placed glycolysis/lactate efflux downstream of SLC16A3 and upstream of M2 macrophage polarization in lung adenocarcinoma.

    Evidence Seahorse, glucose/lactate assays, pHrodo, flow cytometry, glycolysis-inhibitor rescue, and in vivo allograft model

    PMID:41432987

    Open questions at the time

    • Receptor coupling lactate to macrophages not identified here
    • Cytokine mediators only partially characterized
13. 2025 Medium

    Revealed a non-transport interaction with the clathrin adaptor AP1G1 that controls AP1G1 membrane enrichment and host susceptibility to respiratory viruses, broadening SLC16A3 function beyond metabolism.

    Evidence Metabolomics, proteomics, thermal proteome profiling, Co-IP, and knockdown with viral infection assays

    PMID:40919783

    Open questions at the time

    • Single Co-IP/TPP interaction without reciprocal validation
    • Whether this requires transport activity is untested
14. 2026 High

    Established that EGF-driven secretory autophagy traffics SLC16A3 and its CD147/BSG chaperone to the plasma membrane via LC3 interaction, a post-transcriptional surface-delivery mechanism driving metastasis.

    Evidence Autophagosome proteomics, LC3-SLC16A3 PLA, TIRF surface imaging, autophagy blockade, and orthotopic TNBC lung-metastasis models

    PMID:41948828

    Open questions at the time

    • LC3-SLC16A3 binding interface undefined
    • Generality across non-TNBC tumors untested
15. 2026 High

    Integrated SLC16A3 lactate export into GPR81-driven autocrine and paracrine circuits—ERK/M2 polarization, CD8⁺ suppression, and c-MYC Ser62 stabilization sustaining glycolysis—and validated MCT4 inhibition plus PD-1 blockade in vivo.

    Evidence In vivo CRISPR metabolic screen, KO/OE lines, Seahorse, flow cytometry, GPR81 antagonism/knockdown, ubiquitination/phosphorylation analysis, and combination therapy in immunocompetent ccRCC

    PMID:42028950

    Open questions at the time

    • Direct GPR81-c-MYC signaling intermediates incompletely mapped
    • VHL-deficiency dependence not generalized beyond ccRCC

• It remains unknown how Ser436 phosphorylation, LC3-mediated trafficking, and the AP1G1 interaction mechanistically alter the transporter's structure or transport cycle, and no structural model of SLC16A3 with its chaperone or inhibitors is available in the corpus.
• No structural/biophysical model of the transport mechanism
• Coupling between post-translational regulation and transport kinetics undefined
• Non-metabolic (AP1G1/viral) role not mechanistically separated from transport